Dr. Mark Walters, MO
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Medical school
- University of California, San Diego School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of California, San Diego School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
CA license G85406 (first issued 1999; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- UCSF Medical Group Business Services (1,598 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $9,212 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $9,212 |
|---|
| Consulting Fee | $9,135 |
|---|---|
| Food and Beverage | $77.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Feb 19, 2025 | Consulting Fee | $6,930 |
| Vertex Pharmaceuticals Incorporated Jun 11, 2025 | Consulting Fee | $2,205 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $190,789 in research payments for these studies, mostly to the institutions running them.
- Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
Genetix Biotherapeutics Inc · Active, not recruiting · NCT02633943 - A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
Genetix Biotherapeutics Inc · Completed · NCT03207009 - A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.